The Life Sciences team advised Red Queen Bio in connection with its spin out from HelixNano and $15 million seed financing round led by OpenAI. Red Queen Bio, a biosecurity-focused startup, will use the funding to advance its mission of developing AI-powered defenses against biological threats. The financing supports the company’s efforts to build safeguards against the misuse of artificial intelligence in the creation of bioweapons and other emerging bio-risks.
Red Queen Bio is an AI biosecurity company developing scalable defenses against AI-enabled biological threats. Backed by OpenAI and other mission-aligned investors, the company partners with frontier labs to identify emerging risks and design countermeasures using advanced models, lab automation, and reinforcement learning. A Public Benefit Corporation, Red Queen Bio is committed to open collaboration to ensure safe, global progress in AI biology.
The Goodwin team was led by Shoaib Ghias, Sam Zucker, Shane Albright, Dan Karelitz, Bartek Sudol and Candace Hagey.
For more information, please read coverage in Reuters.